Group 1 - The Hang Seng Index fell by 0.12% on July 7, with southbound trading totaling HKD 101.765 billion, comprising HKD 56.916 billion in buying and HKD 44.849 billion in selling, resulting in a net inflow of HKD 12.067 billion [1] - The southbound trading through Stock Connect (Shenzhen) had a total turnover of HKD 40.903 billion, with net buying of HKD 6.276 billion, while Stock Connect (Shanghai) had a turnover of HKD 60.862 billion, with net buying of HKD 5.791 billion [1] - The most actively traded stock by southbound funds was Guotai Junan International, with a total turnover of HKD 72.91 billion, followed by Meituan-W and Alibaba-W with turnovers of HKD 51.22 billion and HKD 47.51 billion respectively [1] Group 2 - Among the stocks with significant net buying, the top was the Yingfu Fund with a net inflow of HKD 24.99 billion, despite a closing price drop of 0.16%, followed by Meituan-W with HKD 7.17 billion and China Construction Bank with HKD 6.21 billion [1] - The stocks that saw continuous net buying for more than three days included SMIC, Innovent Biologics, and China Construction Bank, with net buying days of 12, 7, and 3 respectively [2] - The total net buying amount for SMIC was HKD 77.01 billion, followed by Innovent Biologics with HKD 22.89 billion and China Construction Bank with HKD 8.49 billion [2]

Core Insights - On July 7, Health Road made its debut on the Hong Kong Stock Connect active trading list for the first time in a month, indicating increased investor interest [2] - The total trading volume of active stocks on the Hong Kong Stock Connect reached HKD 344.29 billion, accounting for 33.83% of the day's total trading amount, with a net buying amount of HKD 63.29 billion [2] - The top three stocks by trading volume were Guotai Junan International (HKD 72.91 billion), Meituan-W (HKD 51.22 billion), and Alibaba-W (HKD 47.51 billion) [2] Trading Activity Summary - Health Road's trading volume on July 7 was HKD 14.54 billion, with a net buying amount of HKD 0.28 billion, and the stock closed up by 15.27% [2] - The stocks with the highest number of appearances on the active trading list over the past month were Alibaba-W and Tencent Holdings, each appearing 20 times, indicating strong interest from Hong Kong Stock Connect funds [2] - Other notable stocks included Xiaomi Group-W (HKD 31.57 billion), China Construction Bank (HKD 12.28 billion), and Kuaishou-W (HKD 8.83 billion) [2]

Group 1 - On July 7, 2025, Guotai Junan International (01788), Meituan-W (03690), and Alibaba-W (09988) ranked as the top three in southbound trading volume under the Shanghai-Hong Kong Stock Connect, with transaction amounts of 54.57 billion, 30.67 billion, and 24.19 billion respectively [1] - In the southbound trading volume under the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Meituan-W (03690), and Guotai Junan International (01788) also ranked as the top three, with transaction amounts of 23.32 billion, 20.55 billion, and 18.34 billion respectively [1] Group 2 - The top active companies in southbound trading under the Shanghai-Hong Kong Stock Connect included Guotai Junan International (01788) with a net buy of 1.69 billion, Meituan-W (03690) with a net buy of 7.80 billion, and Alibaba-W (09988) with a net buy of 2.00 billion [2] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988) had a net buy of 848.75 million, while Meituan-W (03690) experienced a net sell of 628.12 million [2]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 1.44% on July 7, with a trading volume of 1.402 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 4, 2024, the fund's latest share count was 1.995 billion shares, with a total size of 3.203 billion yuan, reflecting a 404.69% increase in shares and a 747.72% increase in size year-to-date [1] Group 2 - The fund's liquidity showed a cumulative trading amount of 44.415 billion yuan over the last 20 trading days, with an average daily trading amount of 2.221 billion yuan [1] - Year-to-date, the cumulative trading amount reached 96.310 billion yuan over 122 trading days, with an average daily trading amount of 789 million yuan [1] - The current fund manager, Ma Jun, has managed the fund since its inception, achieving a return of 60.51% during the tenure [1] Group 3 - The top holdings of the Hong Kong Innovative Drug ETF include WuXi Biologics (11.47%), BeiGene (10.87%), and Innovent Biologics (9.60%), among others [2] - The fund's holdings are diversified across various companies in the innovative drug sector, with significant investments in both domestic and international firms [2]

Core Viewpoint - The Hong Kong stock market opened lower on July 7, but stablecoin concept stocks rose, with the Hong Kong Stock Connect Technology ETF (513860) showing a year-to-date increase of over 27% [1] Group 1: Market Performance - As of 10:20 AM, the Hong Kong Stock Connect Technology ETF (513860) was flat after a pullback, with notable individual stock performances including Health Road up over 17% and Kuaishou-W up over 3% [1] - The Hong Kong Stock Connect Technology Index increased by 30.85% as of July 4, 2025, while the Hang Seng Index rose by 19.22% and the Hang Seng Technology Index by 16.74% [1] Group 2: Fund Flows - According to Wind data, the Hong Kong Stock Connect Technology ETF (513860) saw a net inflow of 240 million yuan over the past five days, 520 million yuan over the past three months, and 657 million yuan year-to-date [1] Group 3: IPO Activity - In the first half of 2025, there were 42 IPOs in Hong Kong, raising over 107 billion HKD, which is approximately 22% more than the total for the previous year, making Hong Kong the global leader in IPO fundraising [1] Group 4: Valuation Metrics - The Hang Seng Index had a TTM price-to-earnings (P/E) ratio of 10.68 as of July 1, 2025, with a historical percentile of 63.98% and a dividend yield of 3.93% [1] - The Hang Seng Technology Index had a TTM P/E ratio of 20.10, with a historical percentile of 8.95%, indicating a relatively low valuation level [1]

Group 1 - The core viewpoint of the event emphasizes the significant market growth potential of new therapies such as cell and gene therapy, bispecific antibodies, and antibody-drug conjugates (ADCs), alongside the rapid development of artificial intelligence providing more possibilities for disease treatment [1] - The Chinese innovative drug industry has been accelerating its international expansion, with a notable increase in the accessibility of innovative biopharmaceuticals over the past decade [1] - The establishment of a standardized clinical-grade stem cell resource bank is identified as a core support for the sustainable development of the industry, necessitating simultaneous advancements in technological innovation and ethical regulations [1] Group 2 - The roundtable discussion highlighted the shift in human health perspectives from "fighting diseases" to "controlling life quality," driven by breakthroughs in emerging biotechnologies [2] - The event aims to bridge the gap between academia and industry, fostering cross-disciplinary exchanges to explore new paradigms and pathways for technological innovation [2] - Future discussions will focus on cutting-edge technologies such as artificial intelligence, photonics, and synthetic biology, promoting the integration of future technologies with future industries [2]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [9]. Core Insights - The pharmaceutical index increased by 3.64% during the week of June 30 to July 4, outperforming both the ChiNext and CSI 300 indices, indicating a positive market sentiment towards innovative drugs and brain-computer interface technologies [14][15]. - The report emphasizes the strong performance of PD-1 Plus drugs, which are seen as a driving force in the current market recovery, supported by significant business development (BD) deals and a favorable industry trend [2][15]. - The outlook for 2025 remains optimistic, focusing on innovative drugs, new technologies, and the restructuring of supply chains [3][16]. Summary by Sections 1. Industry Overview - The pharmaceutical sector is experiencing a rebound, with innovative drugs and brain-computer interfaces leading the charge. The report highlights the importance of PD-1 Plus drugs in this recovery [14][15]. 2. Innovative Drug Selection - PD-1 Plus drugs are gaining traction, with significant overseas collaborations and clinical trial advancements. The report notes that companies like Innovent Biologics and BeiGene are at the forefront of this trend [20][21]. - The report suggests focusing on companies with promising PD-1/IL-2 combinations and those that have successfully entered international markets [23]. 3. Investment Strategies - The report outlines a strategy focusing on core stocks in the innovative drug space, particularly those with strong growth potential and upcoming clinical data releases [3][17]. - Key companies to watch include Innovent Biologics, Zai Lab, and others involved in PD-1 Plus and related technologies [4][17]. 4. Market Performance - The report provides a comparative analysis of the performance of various indices, noting that the innovative drug index has outperformed the broader pharmaceutical index and the CSI 300 index since the beginning of 2025 [41][42]. - The report also highlights the performance of specific stocks within the innovative drug sector, indicating a positive trend for companies like Zai Lab and BeiGene [45]. 5. Future Outlook - The report anticipates continued optimism in the pharmaceutical sector, particularly around innovative drugs and new technologies such as AI in healthcare and rehabilitation robotics [3][16]. - The focus will be on identifying high-growth opportunities in the innovative drug space and leveraging the ongoing restructuring of supply chains [3][19].

Core Insights - The data indicates significant trading volume increases for various companies, suggesting heightened investor interest and potential market movements [1][2][3][4][5] Group 1: Companies with Notable Volume Increases - 阳光能源 (00757) reported a volume ratio of 2.35, indicating strong trading activity [2] - 长城汽车 (02333) had a volume ratio of 2.21, reflecting increased investor engagement [2] - 郑煤机 (00564) showed a volume ratio of 1.92, suggesting a notable rise in trading [2] Group 2: Additional Companies with Increased Trading Activity - 万国数据-SW (09698) recorded a volume ratio of 1.83, indicating significant market interest [2] - 映恩生物-B (09606) had a volume ratio of 1.78, reflecting heightened trading activity [2] - 超盈国际控股 (02111) reported a volume ratio of 1.71, suggesting increased investor focus [2] Group 3: Companies with Moderate Volume Ratios - 中国能源建设 (03996) had a volume ratio of 1.70, indicating a solid level of trading activity [2] - 亚信科技 (01675) reported a volume ratio of 1.60, reflecting moderate investor interest [2] - 金宝通 (00320) showed a volume ratio of 1.53, suggesting a rise in trading volume [2] Group 4: Companies with Lower Volume Ratios - 中国水务 (00855) had a volume ratio of 1.52, indicating stable trading activity [2] - 广汽集团 (02238) reported a volume ratio of 1.52, reflecting consistent investor engagement [2] - 凯莱英 (06821) showed a volume ratio of 1.52, suggesting steady trading interest [2]

Innovent Biologics Overview - Innovent Biologics has grown into a China-leading biopharmaceutical company with 16 commercial products and 21 clinical pipeline products[9,10] - Innovent's total revenue exceeded RMB9.4 billion in 2024, marking a 55% increase from the previous year[26,27] - Product revenue is projected to achieve RMB20 billion in 2027[38] Oncology Drug Development in China - China accounted for 35% of the global oncology trials in 2023, exceeding the US[172] - The share of first-approved innovative drugs developed by China rose significantly from 4% in 2015 to 38% in 2024[175] - In the first half of 2025, Chinese pharmaceutical companies executed 20 oncology out-licensing deals totaling nearly $30 billion, with ADCs remaining a key focus[185,187] IBI363 (PD-1/IL-2 α-bias) Clinical Progress - IBI363 is a global first-in-class next-generation IO therapy designed to selectively activate and expand tumor-specific T cells[158,159] - In IO-resistant squamous cell lung cancer, IBI363 at 3 mg/kg showed a confirmed ORR of 36.7% and a median PFS of 9.3 months[160] - In IO-resistant melanoma, IBI363 showed an ORR of 26.7% and a median DoR of 14 months[531,533] - In 3L+ CRC, IBI363 monotherapy achieved a median OS of 16.1 months, and IBI363 + Bevacizumab combination therapy showed a cORR of 15.1%[647,650] ADC Developments in Gastrointestinal Cancers - HER2 ADCs demonstrated remarkable efficacy in HER2 3+ CRC, with T-DXd showing a 57.5% ORR and IBI354 showing a 54% confirmed ORR in earlier-phase trials[203,204] - IBI343, a CLDN18.2 ADC, showed promising efficacy in 3L gastric cancer, with the 6 mg/kg group achieving an ORR of 36.7% and a median PFS of 6.8 months[214,217] - In advanced pancreatic cancer, IBI343 showed an ORR of 22.7% in CLDN18.2-high (IHC ≥60%) population, with mPFS of 5.4 months and mOS of 9.1 months[220,224]

Core Insights - On July 4, 2025, Guotai Junan International (01788), Alibaba-W (09988), and SMIC (00981) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 10.714 billion, 3.571 billion, and 3.184 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Guotai Junan International (01788), Alibaba-W (09988), and Xiaomi Group-W (01810) also led the trading volume, with amounts of 3.641 billion, 3.489 billion, and 2.435 billion respectively [1] Southbound Stock Connect (Shanghai-Hong Kong) - Top active companies by trading volume: - Guotai Junan International (01788): 10.714 billion, net buy of 91.5226 million [2] - Alibaba-W (09988): 3.571 billion, net sell of 334 million [2] - SMIC (00981): 3.184 billion, net buy of 37.2 million [2] - Xiaomi Group-W (01810): 3.087 billion, net sell of 370 million [2] - Meituan-W (03690): 2.379 billion, net sell of 270 million [2] - China Construction Bank (00939): 2.120 billion, net buy of 168 million [2] - XPeng Inc. (09868): 2.108 billion, net buy of 919 million [2] - Tencent Holdings (00700): 1.900 billion, net sell of 145 million [2] - CanSino Biologics (09926): 1.674 billion, net sell of 95.5519 million [2] - Dmall (02586): 1.249 billion, net buy of 30.1596 million [2] Southbound Stock Connect (Shenzhen-Hong Kong) - Top active companies by trading volume: - Guotai Junan International (01788): 3.641 billion, net buy of 50.5414 million [2] - Alibaba-W (09988): 3.489 billion, net sell of 1.153 billion [2] - Xiaomi Group-W (01810): 2.435 billion, net sell of 443 million [2] - SMIC (00981): 1.969 billion, net buy of 39.6 million [2] - Tencent Holdings (00700): 1.777 billion, net sell of 28.7313 million [2] - CanSino Biologics (09926): 1.675 billion, net buy of 19.5 million [2] - Meituan-W (03690): 1.660 billion, net buy of 96.5584 million [2] - XPeng Inc. (09868): 1.480 billion, net sell of 462.813 million [2] - Innovent Biologics (01801): 819 million, net buy of 18.2291 million [2] - China Mobile (00941): 622 million, net buy of 47.7507 million [2]